ReviewTargeted oncology2013
Follistatin as potential therapeutic target in prostate cancer.
Review in Targeted oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- High Expression of Follistatin is a Risk Factor Predicting Poor Overall Survival in Hepatocellular Carcinoma Patients.Journal of hepatocellular carcinoma · 2026Article
- Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advancedTranslational lung cancer research · 2023Article
- Immunostaining of βA-Activin and Follistatin Is Decreased in HPV(+) Cervical Pre-Neoplastic and Neoplastic Lesions.Viruses · 2023Article
- Article
- Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.Endocrine-related cancer · 2021Article
- Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.Pathology oncology research : POR · 2021Article
- Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia.EMBO molecular medicine · 2020Article
- Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.Breast cancer research : BCR · 2017Article
- Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.BMC cancer · 2016Article
- Observational
- Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression.Journal of proteomics · 2014Article
- Article
- Clinical and Therapeutic Implications of Follistatin in Solid Tumours.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follistatin is a single-chain glycosylated protein whose primary function consists in binding and neutralizing some members of the transforming growth factor-β superfamily such as activin and bone morphogenic proteins. Emerging evidence indicates that this molecule may also play a role in the malignant progression of several human tumors including prostate cancer. In particular, recent findings suggest that, in this tumor, follistatin may also contribute to the formation of bone metastasis through multiple mechanisms, some of which are not related to its specific activin or bone morphogenic proteins' inhibitory activity. This review provides insight into the most recent advances in understanding the role of follistatin in the prostate cancer progression and discusses the clinical and therapeutic implications related to these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.